References
[1] Mackey M, Glisovic S, Pastore Y, Krajinovic M, Craig M. The
timing of cyclic cytotoxic chemotherapy can worsen neutropenia and
neutrophilia. Brit J Clin Pharmacol 2020; EPub Ahead of Print.
[2] Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi
H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L,
Zalcman G, Albiges L, Escudier B, Routy B. Negative association of
antibiotics on clinical activity of immune checkpoint inhibitors in
patients with advanced renal cell and non-small-cell lung cancer. Ann
Oncol 2018; 29: 1437-1444.
[3] Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of
baseline neutrophil-to-lymphocyte ratio in patients receiving immune
checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther
2018 23; 11:955-965
[4] Barbolosi D, Ciccolini J, Lacarelle B, Barlési F, André N.
Computational oncology–mathematical modelling of drug regimens for
precision medicine. Nat Rev Clin Oncol 2016; 13:242-54.
[5] Ferrer F, Fanciullino R, Milano G, Ciccolini J. Towards Rational
Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and
Combinations Clin Pharm Ther 2020; EPub Ahead of Print.
[6] Friberg LE, Karlsson MO. Mechanistic Models for
Myelosuppression. Investigational New Drugs 2003; 21: 183–194.
[7] Meille C, Barbolosi D, Ciccolini J, Freyer G, Iliadis A.
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic
Mathematical Modeling: Densification and Intensification of Combination
Cancer Therapy. Clin Pharmacokinet 2016; 55:1015-25.
[8] Hénin E, Meille C, Barbolosi D, You B, Guitton J, Iliadis A,
Freyer G. Revisiting dosing regimen using PK/PD modeling: the MODEL1
phase I/II trial of docetaxel plus epirubicin in metastatic breast
cancer patients. Breast Cancer Res Treat 2016; 156: 331-41.
[9] Craig M, Humphries AR, Mackey M. mathematical model of
granulopoiesis incorporating the negative feedback dynamics and kinetics
of G-CSF/neutrophil binding and internalisation. Bull Math Biol 2016;
78: 2304–2357.